Ads
related to: fda approved intrathecal drugs for prostate cancer patients advice free- Mechanism of Disease
Disease Information & Implications
Of Treatment with XTANDI®
- Clinical Trial Data
View Clinical Data & Results
From a Pivotal Trial for XTANDI®
- HCP Access & Support
Explore HCP Support Information and
Coverage Tools For Patients.
- Prescribing Information
View Prescribing Information
For XTANDI® (enzalutamide).
- Mechanism of Disease
perfectfaqs.com has been visited by 100K+ users in the past month
Search results
Results from the WOW.Com Content Network
Gallium (68 Ga) gozetotide or Gallium (68 Ga) PSMA-11 sold under the brand name Illuccix among others, is a radiopharmaceutical made of 68 Ga conjugated to prostate-specific membrane antigen (PSMA) targeting ligand, Glu-Urea-Lys(Ahx)-HBED-CC, used for imaging prostate cancer by positron emission tomography (PET). [11]
It is a microtubule inhibitor, [2] and the fourth taxane to be approved as a cancer therapy. [citation needed] Cabazitaxel was developed by Sanofi-Aventis and was approved by the US Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer in June 2010. [5] [6] [7] It is available as a generic medication. [8] [9]
Padeliporfin, sold under the brand name Tookad, is a medication used to treat men with prostate cancer. [1] [2] It is used in the form padeliporfin di-potassium.[2]The most common side effects include problems with urinating (pain, inability to pass urine, strong urge to pass urine, frequent urination, and incontinence), sexual problems (erectile dysfunction and ejaculation failure), blood in ...
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Abiraterone acetate was FDA approved in April 2011 for treatment of castration-resistant prostate cancer for patients who have failed docetaxel therapy. Abiraterone acetate inhibits an enzyme known as CYP17, which is used in the body to produce testosterone.
In the early 1990s, the U.S. Food and Drug Administration approved a test called the PSA—or prostate-specific antigen—for early detection of prostate cancer. The simple blood draw detects a ...
Ads
related to: fda approved intrathecal drugs for prostate cancer patients advice freeperfectfaqs.com has been visited by 100K+ users in the past month